Cell-free protein expression is an essential tool for molecular biologists in basic as well as applied sciences. Cell-free protein expression is increasingly being adopted by researchers in high-throughput functional proteomics and genomics, as it has significant advantages over protein expression in living cells. Cell-free protein expression is essential for enzyme engineering using display technologies and the generation of protein arrays, such as nucleic acid programmable protein array (NAPPA). Cell-free protein expression requires a DNA template (which can be either a plasmid or a polymerase chain reaction product) encoding the target protein, and a solution containing all the necessary components such as translation factors, transcription factors, enzymes, and others to carry out transcription and translation. This solution is a cell-free extract, as it consists only the organelle and cytosolic material while the cell membrane has been removed. When the genetic material and the cell-free extract are combined, expression of the target protein can start.
Global cell-free protein expression market is estimated to be valued at US$ 280.2 million in 2022 and is expected to exhibit a CAGR of 6.4% over the forecast period (2022-2030).
Figure 1. Global Cell-Free Protein Expression Market Share (%), By Region, 2022
Rising cases of chronic diseases such as cancer, diabetes, cardiovascular disease, and others creates a demand for personalized medicine which can be achieved using cell-free protein expression. This is expected to drive growth of the global cell-free protein expression market over the forecast period.
For instance, according to data published in the International Diabetes Federation (IDF) Diabetes Atlas Tenth edition 2021, in December 2021, it is estimated that around 537 million adults (20-79 years) were suffering from diabetes across the globe in 2021. The same source also estimates that the total number of people suffering from diabetes will rise to around 643 million by 2030 and 783 million by 2045, globally.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2021 | Market Size in 2022: | US$ 280.2 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2022 to 2030 |
| Forecast Period 2022 to 2030 CAGR: | 6.4 % | 2030 Value Projection: | US$ 459.9 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Inc., Takara Bio, Inc., Promega Corporation, New England Biolabs, Jena Bioscience GmbH, GeneCopoeia, Inc., Cube Biotech GmbH, CellFree Sciences Co., Ltd., Moderna Therapeutics, Biotechrabbit GmbH, Bioneer Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Daicel Arbor Biosciences Daicel Arbor Biosciences, Profacgen, Creative Biolabs, biotechrabbit, Roche Molecular Systems, Inc., Cusabio Technology LLC, and LenioBio |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Cell-Free Protein Expression Market Value (US$ Mn), By Product Type, 2022
Increasing marketing strategies by key players to increase awareness about advancements in their cell-free protein expression systems is expected to drive market growth over the forecast period.
For instance, on June 1, 2022, Codex DNA, Inc., a U.S.-based synthetic biology company announced that it would be presenting its BioXp system and RapidAMP technology for antibody and protein engineering workflows at Antibody Engineering and Therapeutics Europe Conference held from June 7 to 9, 2022. BioXp system provides hands-free, end-to-end automation of DNA assembly, cloning, amplification, and mRNA synthesis in a single run.
Global Cell-Free Protein Expression Market – Impact of Coronavirus (Covid-19) Pandemic
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was first reported from Wuhan, China in December 2019, and was declared as a global pandemic by the World Health Organization (WHO), which designates this SARS-CoV-2 infection as novel Coronavirus (COVID-19). According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread across the globe infecting over 523 million population leading to more than 6.3 million deaths as of June 5, 2022. The negative impact of COVID-19 on the healthcare domain is huge and it has significantly disrupted the healthcare industries’ entire supply chain, from raw materials to manufacturing and delivery. However, the COVID-19 pandemic had a positive impact on the overall growth of the cell-free protein expression market, owing to use of cell-free protein expression systems to develop new tools, vaccines, and treatments for COVID-19 patients.
For instance, in November 2021, researchers from the North-western University, U.S., developed a cell-free, high-throughput, automated screening platform to rapidly identify anti-severe acute respiratory syndrome coronavirus (SARS-CoV-2) antibodies generated in response to COVID-19 vaccines. These antibodies have high efficacy in preventing SARS-CoV-2 infection and symptomatic disease. In addition to therapeutic usage, these antibodies are widely used in immunoassays for the rapid detection of viral antigens.
Global Cell-Free Protein Expression Market - Restraint
High cost of protein expression systems and lack of effective systems for post-translational modifications are the factors that are expected to hinder growth of the global cell-free protein expression market over the forecast period.
Cell-free protein expression systems are not feasible for large-scale protein expression, as it can turn into a capital-intensive process due to expensive reagents such as phosphate chemicals in nucleotide form and secondary energy sources.
Moreover, the addition of energy and substrate sources in the process can have a negative impact on the cell-free protein expression systems due to short reaction scales which lead to the limited ability of resultant protein foldings during protein expression.
Key Players
Major players operating in the global cell-free protein expression market include Thermo Fisher Scientific, Inc., Takara Bio, Inc., Promega Corporation, New England Biolabs, Jena Bioscience GmbH, GeneCopoeia, Inc., Cube Biotech GmbH, CellFree Sciences Co., Ltd., Moderna Therapeutics, Biotechrabbit GmbH, Bioneer Corporation, Merck KGaA, Bio-Rad Laboratories, Inc., Daicel Arbor Biosciences Daicel Arbor Biosciences, Profacgen, Creative Biolabs, biotechrabbit, Roche Molecular Systems, Inc., Cusabio Technology LLC, and LenioBio
Cell-free protein expression, also known as in vitro translation, in vitro protein expression, cell-free translation, or cell-free protein synthesis, is the production of recombinant proteins in cell lysates rather than within cultured cells. Cell-free protein expression uses the biomolecular machinery with all the components extracted from the desired cell type. Cell-free protein expression system is a rapid, simple, and sensitive tool that is devoid of membrane-bound barriers, yet contains all the mandatory substrates, machineries and biomolecules which are required for the synthesis of the desired proteins. Cell-free protein expression system is a powerful tool in biological research as it can be used for numerous applications such as assembly of viruses, expansion of genetic code, in metabolic engineering for production of toxic and complex proteins, etc. In order to produce a protein of interest, cell-free protein expression systems use crude extracts such as Escherichia coli, rabbit reticulocytes, wheat germ (WGE), insect cells, or commercially available systems of purified recombinant elements (PURE).
Market Dynamics
Increasing prevalence of chronic diseases, such as cancer, growing demand for targeted and personalized medicine, rising research and development activities by market players, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global cell-free protein expression market over the forecast period.
For instance, according to data published in the GLOBOCAN 2020 report by the Global Cancer Observatory in December 2020, it is estimated that around 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and around 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) were reported in 2020, globally.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients